西妥昔单抗治疗晚期直肠腺癌1例
摘要
结直肠癌是常见的消化道恶性肿瘤，约25％的患者在初诊时已有潜在转移，另50％患者在病程中出现转移。自20世纪90年代后期开始应用奥沙利铂、伊立替康等药物后，晚期结直肠癌的治疗有效率及生存期均显著提高；近年来随着靶向治疗药物的出现，晚期结直肠癌的治疗又上了一个新的台阶。
出处
《癌症进展》
2012年第6期641-644,共4页
Oncology Progress
参考文献13
-
1Van Cuts em E, Kohne CH, Hitre E, et a1. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer [J]. N EnglJ Med, 2009, 360 (14): 1408 -1417.
-
2Saltz LB, Meropol NJ, Loehrer PJ Sr , et al. Phase II trial of cetuximab in patients with refraetory colorectal cancer that expresses the epidermal growth factor receptor [J].J Clin Oncol, 2004, 22 (7): 1201 - 1208.
-
3Cunningham D, Humblet Y, Siena S, et a1. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecanrefractory metastatic colorectal cancer [J]. N EnglJ Merl, 2004,351 (4):337 -345.
-
4Venook A, Niedzwiecki D, Hoillis D, et a1. Phase ill study of irinotecan + 5-FU/LV (FOLFIRI) or oxaliplatin + 5-FU/LV (FOLFOX) ± cetuximab for patients with untreated metastatic adenocarcinoma of colon and rectal cacer (MCRC): CALGB80203 primary results (abst) [J]. Pro Am Soc Clin Oncol , 2006, 24 (Suppl): 148.
-
5Van C utsem E , Nowacki M, Lang L, et al. Randomized phase ill study of irinotecan and 5-FU/FA with or without cetuximah in the first-line treatment of patients with metastatic colotectal cancer (mCRC): the CRYSTAL tiral [J].JClinOncol, 2007, 25 (SI8):164s.
-
6Van Cuts em E, Lang L, D Haens G, et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRJ with or without cetuximah . the CRYSTAL experience [J].J Clin Oncol , 2008, 26 (Suppl): Abstr 2.
-
7Tejpar S, Peeters M, Humblet Y, et a1. Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan-refractory metastatic colorectal cancer (mCRC), treated with irinotecan (q2w) and escalating doses of cetuximab (ql w): The EVEREST experi- ence (preliminary data) [J].J Clin Oncol , 2008, 26 ( Suppl ) : Abstr 4001 .
-
8Bokemeyer C, Bondarenko I, Hartmann IT, et a1. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab , the OPUS experience [J].J Clin Oncol, 2008, 26 (Suppl): Abstr 4000.
-
9Oe Rooek W,Jonker OJ, Oi Nicolantonio F, et al. Association of KRAS p. G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab [J].JAMA, 2010, 304 (16): 1812 -1820.
-
10Maughan TS, Adams RA, Smith CG, et a1. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial [J]. Lancet, 2011, 377 (9783): 2103 - 2114.
-
1唐复聪,覃怀成.直肠癌多学科综合治疗进展[J].医学综述,2010,16(24):3730-3732. 被引量：1
-
2王秀梅,王云华,王莉彦.1例腹腔镜下胃癌根治术护理配合[J].护理研究（上旬版）,2007,21(10):2627-2628. 被引量：1
-
3胡胜,臧爱华.癌症的靶向性治疗[J].中国肿瘤,2005,14(11):702-705.
-
4李国忠,刘华群,赵良骐,肖颖,王海波,宋文广,王瑞林.重组人血管内皮抑素联合XELOX治疗晚期结直肠癌临床探讨[J].中国肿瘤临床,2009,36(12):688-689. 被引量：4
-
5朱静,马云宝.前列腺癌肿瘤标志物的应用现状及研究进展[J].放射免疫学杂志,2009,22(5):495-498. 被引量：2
-
6周建光,杨梅.前列腺癌标志物研究的新进展[J].临床和实验医学杂志,2010,9(15):1182-1183.
-
7李啸峰,迟宝荣,马琳.大肠癌多药耐药研究进展[J].吉林大学学报（医学版）,2003,29(5):700-702. 被引量：8
-
8张冬梅.结直肠癌辅助化疗进展[J].医学综述,2008,14(9):1334-1336. 被引量：1
-
9张福林.WHO(1999)神经系统肿瘤新分类的特点和应用体会[J].临床与实验病理学杂志,2001,17(5):435-438. 被引量：6
-
10破解癌细胞耐药密码病人生存质量跃上新台阶[J].看医生,2003(5):22-22.
